Faculty Presentations
Ashish M. Kamat, MD |
Fig. 01 -
Title Slide
Fig. 02 -
Disclosures
Fig. 03 -
Why
Fig. 04 -
Overview
Fig. 05 -
BCG Failure
Fig. 06 -
Heterogeneous
Fig. 07 -
Subtypes
Fig. 08 -
Clusters
Fig. 09 -
AUA/SUO
Fig. 10 -
2016 Guideline
Fig. 11 -
BCG vs Cystectomy
Fig. 12 -
Maintenance
Fig. 13 -
ProlongsSurvival
Fig. 14 -
Recurrence-free
Fig. 15 -
Not Created Equal
Fig. 16 -
Papillary Recurrence
Fig. 17 -
Progression-Free vs Disease-Specific
Fig. 18 -
EORTC 30962
Fig. 19 -
Decision Timing
Fig. 20 -
Salvaged Failures
Fig. 21 -
Failure Definition
Fig. 22 -
Review Article
Fig. 23 -
BCG Unresponsive
Fig. 24 -
BC Group Definition
Fig. 25 -
BCG/Interferon
Fig. 26 -
Cancer in situ
Fig. 27 -
Papillary Tumor
Fig. 28 -
Recurrent CIS
Fig. 29 -
Hyperthermic Mitomycin
Fig. 30 -
BCG-unresponsive
Fig. 31 -
Phase 2
Fig. 32 -
Comprehensive Transcriptional Analysis
Fig. 33 -
Progression Events
Fig. 34 -
International BC Group
Fig. 35 -
BCG after TUR
Fig. 36 -
Recurrence
Fig. 37 -
Thank You
TODO, let Pete know of any updates to this content
Six (6) provocative statements concerning clinical treatment of IBD. Each statement is presented as 5 steps:Step 1: the statement & introduction, + 5 possible opinions of that statement -- please choose one
Step 2: a graph of an international survey’s opinions of that statement
Step 3: a literature review for that statement
Step 4: a graph comparing the faculty's vs an international survey’s opinions, + faculty discussion
Step 5: a brief faculty summary, plus the list of references.
Please click on any Statement or any Step tab to read this publication in the order you prefer.